H.C. Wainwright lowered the firm’s price target on MacroGenics (MGNX) to $2 from $4 and keeps a Neutral rating on the shares. The firm says it has been a long time coming for discontinuing clinical development of vobra duo.
H.C. Wainwright lowered the firm’s price target on MacroGenics (MGNX) to $2 from $4 and keeps a Neutral rating on the shares. The firm says it has been a long time coming for discontinuing clinical development of vobra duo.